

Curriculum Vitae

Personal Information

Name: Muh-Hwa Yang (楊慕華)

Gender : male

Date of Birth : 25th September, 1969

Nationality : Taiwan R.O.C.

Address: Institute of Clinical Medicine, National Yang-Ming University, No.155,
Sec.2, Li-Nong Street, Taipei 112, Taiwan

Tel: +886-2-28267000 ext 7911

Fax : +886-2-28235870

Email: mhyang2@vghtpe.gov.tw

Education

- Ph.D., Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan (2006)
- M.D., Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan (1994)

Current Positions

- Vice President, National Yang-Ming University, Taipei, Taiwan (December 2017-present)
- Chair Professor, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan (August 2016-present)
- Director, Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital (November 2015-present)
- Director, Cancer Progression Research Center, National Yang-Ming University, Taipei, Taiwan (February 2018-present)
- Adjunct Research Fellow, Genomic Research Center, Academia Sinica, Taipei, Taiwan (August 2014-present)
- Adjunct Professor, Institute of Biotechnology in Medicine, National Yang-Ming University, Taipei, Taiwan (August 2013-present)
- Adjunct Professor, Department of Biological Science and Technology, National Chao Tung University
- Adjunct Professor, Institute of Clinical Medicine, Taipei Medical University
- Editorial Board, International Journal of Molecular Sciences

Past Positions

- Assistant Professor (2007-2010), Associate Professor (2010-2013), Professor (2013-2016), Acting Director (2017-2018), Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
- Attending Physician, (September 2002-March 2015), Director (March 2015-November 2015), Division of Hematology-Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
- Resident (1996-1999) of Department of Medicine, Chief Resident/Clinical Fellow (1999-2002) of Division of Hematology-Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

Honors and Awards

- Outstanding Research Achievement Award of 60th Anniversary, Taipei Veterans General Hospital (2019)
- Distinguished Thesis, Taipei Veterans General Hospital (2009, 2011, 2013, 2014, 2015, 2017, 2018, 2019)
- Outstanding Research Award, National Science Council/Ministry of Science and Technology, Taiwan (2013-2015, 2016-2018)
- Dr. Chien-Tien Hsu Memorial Award for Outstanding Cancer Research, Taiwan Oncology Society, Taiwan (2015)
- Scientific paper award, Y.Z. Hsu Scientific and Technology Memorial Foundation (2015)
- Award for Junior Research Investigators, Academia Sinica, Taiwan (2011)
- Young Scientist Research Award, Tien-Te Lee Biomedical Foundation, Taiwan (2011)
- Dr. Ta-Cheng Tung Memorial Award for Basic Cancer Research, Taiwan Oncology Society, Taiwan (2009)
- Ta-Yu Wu Memorial Award, National Science Council, Taiwan (2008)

Invited Speeches of International Meetings

- 79th Annual Association of Japanese Cancer Association, Nagoya, Japan (will be held on 1st-3rd Oct, 2020)
- 28th Federation of Asian and Oceanian Biochemists and Molecular Biologists Conference, Colombo, Sri Lanka (will be held on 11th-13th June, 2020)
- Keystone Symposium on Inflammation, Microbiota, and Cancer, Taipei (speaker and local organizing committee member; the meeting is originally planned to be held on May 2020 but is cancelled due to COVID-19)

- 14th Asia Epigenomics Meeting, Taipei (October 2019; speaker and local organizing committee member)
- Advisory Board Meeting for Head and Neck Cancer Treatment in Vietnam, Hanoi (July 2019)
- Asian Society of Head and Neck Oncology, Seoul, Korea (March 2019)
- Asia-Pacific Extracellular Vesicle Conference, Taipei, Taiwan (January 2019)
- 13th Asian Congress on Oral & Maxillofacial Surgery, Taipei, Taiwan (November 2018)
- American Association of Immunology, Austin (TX), USA (May 2018)
- Tech Forum of San Diego American Science and Engineering Association, San Diego (CA), USA (October 2018)
- Invited Speech at Kyushu University, Fukuoka, Japan (November 2018)
- Cross-Strait Stem Cell Forum, Jilin, China (May 2018)
- 1st Cross-Strait Multidisciplinary Research Forum in Biomedical Sciences, Xian, China (November 2017)
- 11th Asia Epigenomics Meeting, Bangalore, India (September 2016)
- Nanchiag Lecture of Biomedical Sciences of Xiamen University, Xiamen, China (April 2016)
- International Symposium of Society of Chinese Bioscientists in America, Taipei, Taiwan (June 2015)
- 8th UST-UCSD Bilateral Symposium, San Diego (CA), USA (November 2014)
- 9th Asia Epigenomics Meeting, Singapore (August 2014)
- Workshops on Cancer and Stem Cell Research, London, UK (September 2012)

Journal Reviewers

Nature Cell Biology, Nature Communications, Science Advances, PLoS Biology, Cancer Research, Oncogene, Molecular Cancer Therapeutics, Molecular Therapy, Theranostics, Journal of Hematology & Oncology, American Journal of Pathology, Cell Death & Diseases, Oral Oncology, Laboratory Investigation, Journal of Cellular and Molecular Medicine, Liver International, PLoS ONE, Journal of Biomedical Science, Journal of Clinical Medicine, BMC Cancer

International Grants Reviewers

Austrian Science Fund, Swiss Cancer Research, Worldwide Cancer Research project grant (U.K.)

Research Interests

My major research interest is to study the pleiotropic effects of epithelial-mesenchymal transition (EMT) during cancer metastasis. EMT is a major mechanism in development and cancer metastasis. However, the knowledge about EMT beyond the induction of cellular disaggregation and migration is limited. Our lab focuses on the multifaceted role of the EMT during cancer progression, including the induction of cancer stemness (Nat Cell Biol 2010), mesenchymal movement in 3-dimensional culture system (Nat Cell Biol 2012), symmetrical division of cancer stem cells (Nat Cell Biol 2014), modulation of cancer cytokinome (Cancer Cell 2014), and collective cell migration (Nat Cell Biol 2019). We also delineate the role of tumor-associated macrophages in regulating epithelial plasticity for tumor colonization (Nat Commun 2018).

In addition to basic cancer biology, I was trained as a hematologist-oncologist and I am also interested in the field of clinical cancer treatment. My major experience is in the treatment of head and neck cancer, which is one of the most devastating male cancers in Taiwan due to habitual betel nut consumption.

Ten Selected Publications (*corresponding author)

1. Li CF, Chen JY, Ho YH, Hsu WH, Wu, LC, Lan HY, Hsu DS, Tai SK, Chang YC*, **Yang MH***. Snail-induced claudin-11 prompts collective migration for tumor progression. *Nat Cell Biol* 2019; 21: 251-262.
2. Lee CC, Lin JC, Hwang WL, Kuo YJ, Chen HK, Tai SK, Lin CC, **Yang MH***. Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization. *Nat Commun* 2018, 9:3763.
3. Pan YR, Chen CC, Chan YT, Wang SJ, Chien FT, Chen YL, Liu JL, **Yang MH***. STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas. *Nat Commun* 2018; 9:3696.
4. Hsu DS, Hwang WL, Yuh CH, Chu CH, Ho YH, Chen PB, Lin HS, Lin HK, Wu SP, Lin CY, Hsu WH, Lan HY, Wang HJ, Tai SK, Hung MC, **Yang MH***. Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer. *Clin Cancer Res* 2017; 23: 4388-4401.
5. Liao TT, Hsu WH, Ho CH, Hwang WL, Lan HY, Lo T, Chang CC, Tai SK, **Yang MH***. let-7 modulates chromatin configuration and target gene repression through regulation of the ARID3B complex. *Cell Rep* 2016;14: 520-533.
6. Hsu DS, Wang SJ, Tai SK, Chou CH, Hsieh CH, Chiu PH, Chen NJ, **Yang MH***. Acetylation of Snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. *Cancer Cell* 2014; 26: 534-548.

7. Hwang WL, Jiang JK, Yang SH, Huang TS, Lan HY, Teng HW, Yang CY, Tsai YP, Lin CH, Wang HW*, **Yang MH***. MicroRNA-146a directs the symmetrical division of Snail-dominant colorectal cancer stem cells. *Nat Cell Biol* 2014;16: 268-280.
8. Yang WH, Lan SY, Huang CH, Tai SK, Tzeng CH, Kao SY, Wu KJ, Hung MC, **Yang MH***. RAC1 activation mediates Twist1-induced cancer cell migration. *Nat Cell Biol* 2012; 14: 366-374.
9. **Yang MH***, Hsu DS, Wang HW, Wang SJ, Lan HY, Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, Chang SY, Lee OK, Wu KJ*. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. *Nat Cell Biol* 2010; 12: 982-992 .
10. **Yang MH#**, Wu MZ#, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ. Direct regulation of TWIST by HIF-1alpha promotes metastasis. *Nat Cell Biol* 2008; 10: 295-305 (#: equal contribution).

Completed Publication List (*corresponding author)

1. Liao TT, Lin CC, Jiang JK, Yang SH, Teng HW, **Yang MH***. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3 in colorectal cancer. *Theranostics* 2020; 10: 6095-6112.
2. Liao TT, **Yang MH***. Hybrid Epithelial/Mesenchymal State in Cancer Metastasis: Clinical Significance and Regulatory Mechanisms. *Cells* 2020; 9:623 (review article).
3. Sun NY, **Yang MH***. Metabolic reprogramming and epithelial-mesenchymal plasticity: opportunities and challenges for cancer therapy. *Front Oncol* 2020 DOI: 10.3389/fonc.2020.00792 (review article).
4. Chien SH, Liu HM, Chen PM, Ko PS, Lin JS, Chen YJ, Lee LH, Hsiao LT, Chiou TJ, Gau JP, **Yang MH**, Liu CY. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors. *Hematol Oncol* 2020 Feb 3. doi: 10.1002/hon.2721
5. Grünwald V, Chirovsky D, Cheung WY, Bertolini F, Ahn MJ, **Yang MH**, Castro G, Berrocal A, Sjoquist K, Kuyas H, Auclair V, Guillaume X, Joo S, Shah R, Harrington K; GLANCE H&N STUDY Investigators. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. *Oral Oncol* 2020;102:104526.
6. Yan X, Cao N, Chen Y, Lan HY, Cha JH, Yang WH, **Yang MH***. MT4-MMP promotes invadopodia formation and cell motility in FaDu head and neck cancer

- cells. *Biochem Biophys Res Commun* 2020; 522:1009-1014.
7. Chen TH, Chang PM, **Yang MH***. Novel immune-modulating drugs for advanced head and neck cancer. *Head Neck*. 2019;41(Suppl 1):46-56 (review article).
 8. Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, **Yang MH**, Chang TS, Huang YH. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. *J Exp Clin Cancer Res* 2019; 38: 474.
 9. Lee TL, Chiu PH, Li WY, **Yang MH**, Wei PY, Chu PY, Wang YF, Tai SK. Nerve-tumour interaction enhances the aggressiveness of oral squamous cell carcinoma. *Clin Otolaryngol* 2019; 44: 1087-1095.
 10. Lai CH, Tsai WS, **Yang MH**, Chou TY, Chang YC. A two-dimensional immunomagnetic nano-net for the efficient isolation of circulating tumor cells in whole blood. *Nanoscale* 2019; 11: 21119-21127.
 11. Lu HJ, Hsieh CC, Yeh CC, Yeh YC, Wu CC, Wang FS, Lai JM, **Yang MH**, Wang CH, Huang CF, Chang PM. Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy. *Sci Rep* 2019; 9: 12913.
 12. Yen CC, Chen SC, Hung GY, Wu PK, Chua WY, Lin YC, Yen CH, Chen YC, Wang JY, **Yang MH**, Chao Y, Chang MC, Chen WM. Expression profile-driven discovery of AURKA as a treatment target for liposarcoma. *Int J Oncol* 2019; 55: 938-948.
 13. Ho WT, Chang JS, Chou SF, Hwang WL, Shih PJ, Chang SW, **Yang MH**, Jou TS, Wang IJ. Targeting non-muscle myosin II promotes corneal endothelial migration through regulating lamellipodial dynamics. *J Mol Med (Berl)* 2019; 97: 1345-1357.
 14. Chen MH, Chang SC, Lin PC, Yang SH, Lin CC, Lan YT, Lin HH, Lin CH, Lai JI, Liang WY, Lu ML, **Yang MH**, Chao Y. Combined microsatellite instability and elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) might be a more promising immune biomarker in colorectal cancer. *Oncologist* 2019; 24: 1534-1542.
 15. Yen CC, Chen LT, Li CF, Chen SC, Chua WY, Lin YC, Yen CH, Chen YC, **Yang MH**, Chao Y, Fletcher JA. Identification of phenothiazine as an ETV1-targeting agent in gastrointestinal stromal tumors using the Connectivity Map. *Int J Oncol* 2019 ;55: 536-546.
 16. Cheng WC, Liao TT, Lin CC, Yuan LE, Lan HY, Lin HH, Teng HW, Chang HC, Lin CH, Yang CY, Huang SC, Jiang JK, Yang SH, **Yang MH***, Hwang WL*.

RAB27B-activated secretion of stem-like tumor exosomes delivers the biomarker microRNA-146a-5p, which promotes tumorigenesis and associates with an immunosuppressive tumor microenvironment in colorectal cancer. *Int J Cancer* 2019;145:2209-2224.

17. Li CF, Chen JY, Ho YH, Hsu WH, Wu, LC, Lan HY, Hsu DS, Tai SK, Chang YC*, **Yang MH***. Snail-induced claudin-11 prompts collective migration for tumor progression. *Nat Cell Biol* 2019; 21:251-262.
18. Hwang WL*, Lan HY, Cheng WY, Huang SC, **Yang MH***. Tumor stem-Like cells-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. *J Hematol Oncol* 2019;12:10.
19. Lee CC, Lin JC, Hwang WL, Kuo YJ, Chen HK, Tai SK, Lin CC, **Yang MH***. Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization *Nat Commun* 2018; 9: 3763.
20. Pan YR, Chen CC, Chan YT, Wang SJ, Chien FT, Chen YL, Liu JL, **Yang MH***. STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas. *Nat Commun* 2018 9:3696.
21. Hsieh CH, Tai SK, **Yang MH***. Snail-overexpressing cancer cells promotes M2-like polarization of tumor-associated macrophages by delivering miR-21-abundant exosomes. *Neoplasia* 2018; 20:775-788.
22. Chen YQ, Lan HY, Wu YC, Yang WH, Chiou A*, **Yang MH***. Epithelial-mesenchymal transition softens head and neck cancer cells to facilitate migration in 3D environments. *J Cell Mol Med* 2018 May 4. doi: 10.1111/jcmm.13656.
23. Chen HH, Yu HI, **Yang MH**, Tarn WY. DDX3 activates CBC-eIF3-mediated translation of uORF-containing oncogenic mRNAs to promote metastasis in HNSCC. *Cancer Res* 2018; 78: 4512-4523.
24. Huang KH, Sung IC, Fang WL, Chi CW, Yeh TS, Lee HC, Yin PH, Li AF, Wu CW, Shyr YM, **Yang MH***. Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells. *Oncol Rep* 2018; 40: 294-302.
25. Cheng YJ, Tsai MH, Chiang CJ, Tsai ST, Liu TW, Lou PJ, Liao CT, Lin JC, Chang JT, Tsai MH, Chu PY, Leu YS, Tsai KY, Terng SD, Chien CY, **Yang MH**, Hao SP, Wang CC, Tsai MH, Chen HHW, Kuo C, Wu YH. Adjuvant radiotherapy after curative surgery for oral cavity squamous cell carcinoma and treatment effect of timing and duration on outcome-A Taiwan Cancer Registry national database analysis. *Cancer Med* 2018 Jun 14. doi: 10.1002/cam4.1611.
26. Lin MC, Shueng PW, Chang WK, Mu-Hsin Chang P, Feng HC, **Yang MH**, Lou PJ. Consensus and clinical recommendations for nutritional intervention for

- head and neck cancer patients undergoing chemoradiotherapy in Taiwan. *Oral Oncol* 2018;81:16-21 (review article).
27. Chang PM, Chen CH, Yeh CC, Lu HJ, Liu TT, Chen MH, Liu CY, Wu ATH, **Yang MH**, Tai SK, Mochly-Rosen D, Huang CF. Transcriptome analysis and prognosis of ALDH isoforms in human cancer. *Sci Rep* 2018;8:2713.
 28. Chen SC, Liao TT, **Yang MH***. Emerging roles of epithelial-mesenchymal transition in hematological malignancies. *J Biomed Sci* 2018;25:37 (review article).
 29. Huang KH, Fang WL, Li AF, Liang PH, Wu CW, Shyr YM, **Yang MH***. Caspase-3, a key apoptotic protein, as a prognostic marker in gastric cancer after curative surgery. *Int J Surg* 2018; 52:258-263.
 30. Chen SC, Chang PM, Wang HJ, Tai SK, Chu PY*, **Yang MH***. PD-L1 expression is associated with p16^{INK4A} expression in non-oropharyngeal head and neck squamous cell carcinoma. *Oncol Lett* 2018;1: 2259-2265.
 31. Liang ML, Hsieh TH, Liu YR, Chen YW, Lee YY, Chang FC, Lin SC, Huang MC, Donald Ming-Tak H, Wong TT, Yen Y*, **Yang MH***. Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas. *Oncotarget* 2017;9:2527-2542.
 32. Chou YT, Jiang JK, **Yang MH**, Lu JW, Lin HK, Wang HD, Yuh CH. Identification of a noncanonical function for ribose-5-phosphate isomerase A promotes colorectal cancer formation by stabilizing and activating β -catenin via a novel C-terminal domain. *PLoS Biol* 2018;16:e2003714.
 33. Hung LT, Huang HI, Wang LW, **Yang MH**, Chu PY. Oncologic results and quality of life in patients with squamous cell carcinoma of hypopharynx after transoral laser microsurgery. *Lasers Surg Med* 2018;50:117-124.
 34. Liao TT, **Yang MH***. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness. *Mol Oncol* 2017; 11:792-804 (review article).
 35. Hsu DS, Hwang WL, Yuh CH, Chu CH, Ho YH, Chen PB, Lin HS, Lin HK, Wu SP, Lin CY, Hsu WH, Lan HY, Wang HJ, Tai SK, Hung MC, **Yang MH***. Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer. *Clin Cancer Res* 2017; 23: 4388-4401.
 36. Chang PM, Lu HJ, Wang LW, Tai SK, Chen MH, Chu PY*, **Yang MH***. Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: a phase II study. *Head Neck* 2017; 39: 1333-42.

37. Hwang WL, **Yang MH***. Numb is involved in the non-random segregation of subcellular vesicles in colorectal cancer stem cells. *Cell Cycle* 2016; 15: 2697-2703.
38. Chen SC, Chang PM*, **Yang MH***. Cisplatin/UFUR/irinotecan triple combination therapy for recurrent/metastatic head and neck squamous cell carcinoma—a phase I/II clinical study. *Oncologist* 2016;21: 537-8.
39. Liang ML, Hsieh TH, Ng KH, Tsai YN, Tsai CF, Chao ME, Liu DJ, Chu SS, Chen W, Liu YR, Liu RS, Lin SC, Ho DM, Wong TT*, **Yang MH***, Wang HW. Downregulation of miR-137 and miR-6500-3p promotes cell proliferation in pediatric high-grade gliomas. *Oncotarget* 2016;7: 19723-37.
40. Liao TT, Hsu WH, Ho CH, Hwang WL, Lan HY, Lo T, Chang CC, Tai SK, **Yang MH***. let-7 modulates chromatin configuration and target gene repression through regulation of the ARID3B complex. *Cell Rep* 2016;14: 520-533.
41. Yang WH, Su YH, Hsu WH, Wang CC, Arbiser JL*, **Yang MH***. Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation. *Oncogene* 2016;35:2287-98.
42. Chou YS, **Yang MH***. Epithelial-mesenchymal transition-related factors in solid tumor and hematological malignancy. *J Chin Med Assoc* 2015;78:438-445 (review article).
43. Chen CC, Gau JP, You JY, Huang CE, Chen YY, Lo WH, Cheng YH, Tsai PS, Chou HJ, Tseng YT, Lung J*, **Yang MH***. Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia. *Blood Cancer J* 2015; 5: e339.
44. Hsu DS, Wang SJ, Tai SK, Chou CH, Hsieh CH, Chiu PH, Chen NJ, **Yang MH***. Acetylation of Snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. *Cancer Cell* 2014; 26:534-548.
45. Huang TZ, Chen YJ*, Chou TY, Chen CY, Li HY, Huang BS, Tsai HW, Lan HY, Chang CH, Twu NF, Yen MS, Wang PH, Chao KC, Lee CC, **Yang MH***. Estrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. *J Cell Mol Med* 2014; 18: 1358-1371.
46. Hwang WL, Jiang JK, Yang SH, Huang TS, Lan HY, Teng HW, Yang CY, Tsai YP, Lin CH, Wang HW*, **Yang MH***. MicroRNA-146a directs the symmetrical division of Snail-dominant colorectal cancer stem cells. *Nat Cell Biol* 2014;16: 268-280.

47. Chen YW, Kao SY, Wang SJ, **Yang MH***. Histone modification patterns correlate with patient outcome in oral squamous cell carcinoma. *Cancer* 2013; 119:4259-67.
48. Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, Chen ST, Tai SK, Kuo ML, **Yang MH***. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. *Cancer Res.* 2013;73:4147-4157.
49. Tai SK, Li WY, **Yang MH**, Chu PY, Wang YF. Perineural Invasion in T1 Oral Squamous Cell Carcinoma Indicates the Need for Aggressive Elective Neck Dissection. *Am J Surg Pathol.* 2013;37: 1164-1172
50. Lu HJ, Chen KW, Chen MH, Chu PY, Tai SK, Tzeng CH, Chang PM*, **Yang MH***. Serum Albumin is an Important Prognostic Factor for Carotid Blowout Syndrome. *Jpn J Clin Oncol.* 2013;43:532-539.
51. Kuo YY, Chu PY, Chang SY, Wang YF, Tsai TL, **Yang MH**, Wang LW, Tai SK. Treatment selection for tonsillar squamous cell carcinoma. *J Chin Med Assoc.* 2013;76:211-217.
52. Huang KH, Wang RF, **Yang MH**, Wu CW, Fang WL, Li AF, Chi CW, Kao HL. Advanced gastric cancer patients with lymphoid stroma have better survival than those without. *J Surg Oncol.* 2013;107: 523-528.
53. Yang WH, Lan HY, Tai SK, **Yang MH***. Repression of bone morphogenetic protein 4 by let-7i attenuates mesenchymal migration of head and neck cancer cells. *Biochem Biophys Res Commun.* 2013;433:24-30.
54. Chang CC, **Yang MH**, Lin BR, Chen ST, Pan SH, Hsiao M, Lai TC, Lin SK, Jeng YM, Chu CY, Chen RH, Yang PC, Chin YE, Kuo ML. CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation. *Cell Death Differ.* 2013;20: 443-455.
55. Chou CH, Yang NK, Liu TY, Tai SK, Hsu DS, Chen YW, Chen YJ, Chang CC, Tzeng CH, **Yang MH***. Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer. *Cancer Res.* 2013;73:953-966.
56. Huang KH, Wang RF, **Yang MH**, Wu CW, Fang WL*, Li AF, Chi CW, Kao HL. Advanced gastric cancer patients with lymphoid stroma have better survival than those without. *J Surg Oncol.* 2013;107:523-528.
57. Hung SP, **Yang MH**, Tseng KF, Lee OK. Hypoxia-induced secretion of TGF-beta 1 in mesenchymal stem cell promotes breast cancer cell progression. *Cell Transplant.* 2013; 22: 1869-1882.

58. Chen YW, Chen CY, Chiang SC, Lui MT, Kao SY, **Yang MH***. Predictors and impact of microsurgical complications in patients with locally advanced oral squamous cell carcinoma. *Cancer Sci.* 2012;103:1672-1678.
59. Chua DT, Yiu HH, Seetalarom K, Ng AW, Kurnianda J, Shotelersuk K, Krishnan G, Hong RL, **Yang MH**, Wang CH, Sze WK, Ng WT. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. *Head Neck.* 2012;34: 1225-1230.
60. Huang WY, Lin CC, Jen YM, Lin KT, **Yang MH**, Chen CM, Chang YN, Sung FC, Kao CH*. Association between adult otitis media and nasopharyngeal cancer: A nationwide population-based cohort study. *Radiother Oncol.* 2012; 104: 338-342.
61. Chung CY, Lin SF, Chen PM, Chang MC, Kao WY, Chao TY, Hsiao LT, Yen CC, **Yang MH**, Hwang WS, Lin TL, Chiou TJ, Chang CS*. Thalidomide for the treatment of myelodysplastic syndrome in Taiwan: results of a phase II trial. *Anticancer Res* 2012; 32: 3415-3419.
62. Chen YW, Kao SY, **Yang MH***. Analysis of p16(INK4A) expression of oral squamous cell carcinomas in Taiwan: prognostic correlation without relevance to betel quid consumption. *J Surg Oncol.* 2012; 106: 149-54.
63. Yu YB, Gau JP, Liu CY, **Yang MH**, Chiang SC, Hsu HC, Hong YC, Hsiao LT, Liu JH, Chiou TJ, Chen PM, Lee TS, Chou LF, Tzeng CH, Chen TJ*. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. *Thromb Haemost* 2012;108: 225-235.
64. Tai SK*, Li WY, **Yang MH**, Chang SY, Chu PY, Tsai TL, Wang YF, Chang PM. Treatment for T1-2 oral squamous cell carcinoma with or without perineural invasion: neck dissection and postoperative adjuvant therapy. *Ann Surg Oncol* 2012;19:1995-2002.
65. **Yang MH**, Lin BR, Chang CH, Chen ST, Lin SK, Kuo MY, Jeng YM, Kuo ML, Chang CC*. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. *Oncogene.* 2012;31: 2401-2411.
66. Yang WH, Lan HY, Huang CH, Tai SK, Tzeng CH, Kao SY, Wu KJ, Hung MC, **Yang MH***. RAC1 activation mediates Twist1-induced cancer cell migration. *Nat Cell Biol.* 2012;14:366-374.
67. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, **Yang MH**, Hortobagyi GN, Hung MC*. Epithelial-mesenchymal transition induced by TNF- α requires NF- κ B-mediated transcriptional upregulation of Twist1. *Cancer Res.* 2012; 72: 1290-1300.

68. Chen KW, Liu CJ, Lu HJ, Tzeng CH, Liu JH, Chiou TJ, Yen CC, Wang WS, Chao TC, Teng HW, Chen MH, Liu CY, Chang PM, **Yang MH**. Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study. *BMC Res Notes*. 2012;5: 70
69. Lu HJ, Chen KW, Tzeng CH, Liu JH, Chiou TJ, Yen CC, Chao TC, Teng HW, Chen MH, Liu CY, Wang WS, Chang PM, **Yang MH**. Evaluation of prognosis for carcinoma of unknown origin in elderly patients. *Oncology*. 2012; 83: 24-30.
70. Wu KJ, **Yang MH**. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connection. *Biosci Rep* 2011;31: 449-55.
71. Chang PM, Tzeng CH, Chen MH, Tsao CJ, Su WC, Hwang WS, Chang YF, Chang SY, **Yang MH***. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. *Cancer Chemother Pharmacol*. 2011;68:1477-1484..
72. Hsieh YY, Mu-Hsin Chang P, Chen MH, Chu PY, Tzeng CH, Chang SY, Chen PM, **Yang MH***. Pretreatment risk stratification for non-metastatic head and neck squamous cell carcinoma in a high-prevalence area. *J Chin Med Assoc*. 2011;74:487-492.
73. Tsai TL, Chu PY, Tai SK, Wang YF, **Yang MH**, Wang LW, Lirng JF, Chang SY*. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma. *Jpn J Clin Oncol* 2011; 41: 1182-1193.
74. Wu MZ, Tsai YP, **Yang MH**, Huang CH, Chang SY, Chang CC, Teng SC, Wu KJ. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. *Mol Cell* 2011; 43: 811-22.
75. Pan JJ, **Yang MH***. The role of epithelial-mesenchymal transition in pancreatic cancer. *J Gastrointest Oncol* 2011;2: 151-156.
76. Hwang WL†, **Yang MH†**, Tsai ML, Lan HY, Su SH, Chang SC, Teng HW, Yang SH, Lan YT, Chiou SH, Wang HW. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. *Gastroenterology*. 2011; 141: 279-291, 291.e1-5. (†: equal contribution).
77. Huang YC, Chang PM, Chen MH, Chu PY, Tzeng CH, Chang SY, **Yang MH***. A study using ifosfamide and etoposide in patients with cisplatin-refractory recurrent or metastatic head and neck squamous cell carcinoma. *Jpn J Clin Oncol*. 2011;41:630-636.
78. Tai SK, **Yang MH**, Chang SY, Chang YC, Li WY, Tsai TL, Wang YF, Chu PY, Hsieh SL*. Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. *Cancer Sci*. 2011;102:895-902.

79. Wu KJ, **Yang MH**. Epithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connection. *Biosci Rep* 2011;31: 449-455 (review article).
80. Lo T, Ho JH, **Yang MH**, Lee OK*. Glucose reduction prevents replicative senescence and increases mitochondrial respiration in human mesenchymal stem cells. *Cell Transplant*. 2011;20:813-825.
81. Yang DC, **Yang MH**, Tsai CC, Huang TF, Chen YH, Hung SC. Hypoxia inhibits osteogenesis in human mesenchymal stem cells through direct regulation of RUNX2 by TWIST. *PLoS One*. 2011;6:e23965.
82. Chen YJ, Li HY, Huang CH, Twu NF, Yen MS, Wang PH, Chou TY, Liu YN, Chao KC, **Yang MH***. Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis. *J Pathol*. 2010; 222: 261-270.
83. **Yang MH***†, Hsu DS†, Wang HW, Wang HJ, Lan HY, Yang WH, Huang CH, Kao SY, Tzeng CH, Tai SK, Chang SY, Lee OK, Wu KJ*. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. *Nat Cell Biol* 2010;12: 982-992. (†: equal contribution)
84. Chen MH, Chang PM, Chen PM, Tzeng CH, Chu PY, Chang SY, **Yang MH***. Prolonged facial edema is an indicator of poor prognosis in patients with head and neck squamous cell carcinoma. *Support Care Cancer* 2010;18:1313-1319.
85. Yang JM, Hung CM, Fu CN, Lee JC, Huang CH, **Yang MH**, Lin CL, Kao JY, Way TD. Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation. *J Agric Food Chem* 2010; 58: 10020-10026.
86. Hsu DS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY*, **Yang MH***. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. *Clin Cancer Res* 2010;16:4561-4571.
87. Huang YC, Chang PM, Lee IC, Yang CF, Tzeng CH, **Yang MH***. Duodenal squamous cell carcinoma derived from the hypopharynx: immunohistochemical assessment of metastatic mechanisms. *Gastrointest Endosc* 2010; 72: 460-463.
88. Chen YW, **Yang MH**, Kao SY, Wu CH. A rare complication of acquired factor VIII inhibitors in a postoperative oral cancer patient: a case report. *J Oral Maxillofac Surg* 2010;68: 1989-1993.
89. Chang PM, Hsieh YY, Chen MH, Tzeng CH, Chu PY, Chang SY, Chen PM, **Yang MH***. Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular. *J Chin Med Assoc* 2010;73:292-299.

90. Huang CH, Chen PM, Lu TC, Kung WM, Chiou TJ, **Yang MH**, Kao JY, Wu KJ. Purified recombinant TAT-homeobox B4 expands CD34(+) umbilical cord blood and peripheral blood progenitor cells ex vivo. *Tissue Eng Part C Methods* 2010; 16: 487-496.
91. Hsu DS, Chang SY, Liu CJ, Tzeng CH, Wu KJ, Kao JY*, **Yang MH***. Identification of increased NBS1 expression as a prognostic marker of squamous cell carcinoma of the oral cavity. *Cancer Sci* 2010;101:1029-37.
92. **Yang MH**, Chang PM, Tzeng CH, Chang SY, Chu PY, Tai SK, Tsai TL, Wang YF, Huang JL, Wang HM*, Chen PM*. Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study. *Cancer Chemother Pharmacol.* 2010;65: 259-265.
93. Hsieh YY, **Yang MH***. Deep into the cancer metastasis and development: TWIST activation by hypoxia-inducible factor-1. *J Chinese Oncol Soc* 2009; 25:317-325.
94. Chen MH, Chang PM, Chen PM, Tzeng CH, Chu PY, Chang SY, **Yang MH***. Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. *J Cancer Res Clin Oncol.* 2009;135:1783-1790.
95. Huang CH, Yang WH, Chang SY, Tai SK, Tzeng CH, Kao JY, Wu KJ*, **Yang MH***. Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis. *Neoplasia.* 2009;11: 1371-1382.
96. Hung JJ, **Yang MH**, Hsu HS, Hsu WH, Liu JS, Wu KJ. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. *Thorax.* 2009; 64:1082-1089.
97. **Yang MH**, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu JC. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. *Hepatology.* 2009; 50: 1464-1474.
98. Tsai YP, **Yang MH**, Huang CH, Chang SY, Chen PM, Liu CJ, Teng SC, Wu KJ*. Interaction between HSP60 and beta-catenin promotes metastasis. *Carcinogenesis.* 2009; 30: 1049-1057.
99. Liu CY, Huang LJ, Wang WS, Chen TL, Yen CC, **Yang MH**, Hsiao LT, Liu CY, Chen PM, Chiou TJ*. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. *J Infect* 2009; 58: 154-160.
100. Chang PM, Chen PM, Chu PY, Wang LW, Tai SK, Tsai TL, Huang JL, Wang YF, Chang SY*, **Yang MH***. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study. *Cancer Chemother Pharmacol.* 2008;63:9-17.

101. Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, **Yang MH***. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. *Int J Oncol* 2008;33:549-54.
102. Tai SK, **Yang MH**, Wang LW, Tsai TL, Chu PY, Wang YF, Huang JL, Chang SY*. Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer. *Jpn J Clin Oncol* 2008; 38: 521-527.
103. **Yang MH**, Wu KJ*. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. *Cell Cycle* 2008; 7: 2090-2096.
104. Chang PM, Teng HW, Chen PM, Chang SY, Chu PY, Tsai TL, Tai SK, Wang YF, Huang JL, **Yang MH***. Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer. *J Chin Med Assoc* 2008; 71: 336-341.
105. Chen PM, Yen CC, Wang WS, Lin YJ, Chu CJ, Chiou TJ, Liu JH, **Yang MH***. Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia. *Int J Oncol* 2008; 32: 1335-1341.
106. Lee MY, Chiou TJ, Hsiao LT, **Yang MH**, Lin PC, Poh SB, Yen CC, Liu JH, Teng HW, Chao TC, Wang WS, Chen PM. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. *Ann Hematol* 2008; 87: 285-289.
107. Chen YC, Chiang HY, **Yang MH**, Chen PM, Chang SY, Teng SC, Vanhaesebroeck B, Wu KJ*. Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif. *J Mol Med (Berl)*. 2008; 86: 401-12.
108. Chu Z, Chen JS, Liao CT, Wang HM, Lin YC, **Yang MH**, Chen PM, Gardner ER, Figg WD, Sparreboom A. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. *Anticancer Drugs*. 2008; 19: 275-281.
109. **Yang MH**†, Wu MZ†, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ*. Direct regulation of TWIST by HIF-1alpha promotes metastasis. *Nat Cell Biol* 2008; 10: 295-305. (†:equal contribution)
110. Lin SC, Kau HC, Yang CF, **Yang MH**, Tsai CC, Kao SC, Hsu WM. Adenoid cystic carcinoma arising in the inferior orbit without evidence of lacrimal gland involvement. *Ophthal Plast Reconstr Surg* 2008; 24: 74-6.
111. **Yang MH**, Chang SY, Chiou SH, Liu CJ, Chi CW, Chen PM, Teng SC, Wu KJ. Overexpression of NBS1 induces epithelial-mesenchymal transition and

- co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. *Oncogene* 2007; 26:1459-1467.
112. Lin HL†, **Yang MH**†, Wu CW, Chen PM, Yang YP, Chu YR, Kao CL, Ku HH, Lo JF, Liou JP, Chi CW, Chiou SH. 2-methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer. *Int J Cancer* 2007; 121: 2547-55 (†: equal contribution).
113. Lee MY, **Yang MH**, Liu JH, Yen CC, Lin PC, Teng HW, Wang WS, Chiou TJ, Chen PM. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. *Support Care Cancer* 2007; 15:89-93.
114. **Yang MH**, Chiang WC, Chou TY, Chang SY, Chen PM, Teng SC, Wu KJ. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. *Clin Cancer Res* 2006; 12: 507-515.
115. Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, **Yang MH**, Tseng CH, Chen PM. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. *Biol Blood Marrow Transplant* 2006;12: 84-94.
116. Chen PM, Yen CC, **Yang MH**, Poh SB, Hsiao LT, Wang WS, Lin PC, Lee MY, Teng HW, Bai LY, Chu CJ, Chao SC, Yang AH, Chiou TJ, Liu JH, Chao TC. High prevalence of SV40 infection in patients with nodal non-Hodgkin's lymphoma but not acute leukemia independent of contaminated polio vaccines in Taiwan. *Cancer Invest* 2006; 24: 223-228.
117. Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, **Yang MH**, Chen PM, Lin KP, Chiou TJ. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. *Support Care Cancer* 2006;14: 484-487.
118. Lin PC, Wang WS, **Yang MH**, Yen CC, Chao TC, Hsiao LT, Chen PM. Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer. *J Chin Med Assoc* 2006;69:304-309.
119. **Yang MH**, Yen CC, Chiang SC, Bai LY, Lee KD, Hsiao LT, Chao TC, Wang WS, Liu JH, Chiou TJ, Chen PM. Prognostic significance of clonal diversity of immunoglobulin gene rearrangements in patients with diffuse large B-cell lymphoma. *Oncol Rep* 2005 13: 503-508.
120. Lin JT, Wang WS, Yen CC, Liu JH, **Yang MH**, Chao TC, Chen PM, Chiou TJ. Outcome of colorectal carcinoma in patients under 40 years of age. *J Gastroenterol Hepatol* 2005; 20:900-905.
121. Chao TC, Chu Z, Tseng LM, Chiou TJ, Hsieh RK, Wang WS, Yen CC, **Yang**

- MH**, Hsiao LT, Liu JH, Chen PM. Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial. *Invest New Drugs* 2005; 23:171-177.
122. Lee MY, Chiou TJ, **Yang MH**, Bai LY, Hsiao LT, Chao TC, Tung SL, Wang WS, Yen CC, Liu JH, Chen PM. Relatively favorable outcomes of post-transplant pulmonary function in patients with chronic myeloid leukemia receiving non-myeloablative allogeneic hematopoietic stem cell transplantation. *Eur J Haematol* 2005; 74:152-157.
123. Peng KL, Chen SJ, Lin PY, Hsu WM, **Yang MH**, Tzeng CH, Chen PM. Exudative bullous retinal detachment after peripheral blood stem cell transplantation. *Eye* 2005;19: 603-606.
124. Liu JH, Yen CC, Lin YC, Gau JP, **Yang MH**, Chao TC, Hsiao LT, Wang WS, Tsai YC, Chen PM. Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia. *Leuk Lymphoma* 2004; 45: 2419-2425.
125. Chen PM, **Yang MH**, Hsiao LT, Yu IT, Chu CJ, Chao TC, Yen CC, Wang WS, Chiou TJ, Liu JH. Decreased FHIT protein expression correlates with a worse prognosis in patients with diffuse large B-cell lymphoma. *Oncol Rep* 2004; 11: 349-356.
126. You JY, Chi KH, **Yang MH**, Chen CC, Ho CH, Chau WK, Hsu HC, Gau JP, Liu JH, Chen PM, Chiou TJ. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. *Ann Oncol* 2004 ;15:618-625.
127. Bai LY, Chiou TJ, Liu JH, Yen CC, Wang WS, **Yang MH**, Hsiao LT, Chao TC, Chen PM. Hematopoietic stem cell transplantation for severe aplastic anemia-experience of an institute in Taiwan. *Ann Hematol* 2004; 83:38-43.
128. Liu JH, Wu SC, Chen WS, Yen CC, **Yang MH**, Tsai YC, Chen PM. An intron promotes the anti-*bcr-abl* activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells. *Biochem Biophys Res Commun* 2004; 318:764-772.
129. Lin JT, Lee MY, Hsiao LT, **Yang MH**, Chao TC, Chen PM, Chiou TJ. Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation. *Ann Hematol* 2004; 83:444-446.
130. Bai LY, **Yang MH**, Chiou TJ, Liu JH, Yen CC, Wang WS, Hsiao LT, Chao TC, Chen PM. Non-Hodgkin lymphoma in elderly patients: experience at Taipei Veterans General Hospital. *Cancer* 2003; 98:1188-1195.
131. Lin JT, Wu MS, Wang WS, Yen CC, Chiou TJ, Liu JH, **Yang MH**, Chao TC, Chou SC, Chen PM. All-trans retinoid acid increases Notch1 transcript expression in acute promyelocytic leukemia. *Adv Ther* 2003; 20:337-343.
132. Lin JT, Wang WS, Yen CC, Liu JH, Chiou TJ, **Yang MH**, Chao TC, Chen PM.

- Chryseobacterium indologenes bacteremia in a bone marrow transplant recipient with chronic graft-versus-host disease. *Scand J Infect Dis* 2003; 35:882-883.
133. Yen CC, Chen YJ, Lu KS, Hsia JY, Chen JT, Hu CP, Chen PM, Liu JH, Chiou TJ, Wang WS, **Yang MH**, Chao TC, Lin CH. Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction. *Int J Oncol* 2003 ; 23:871-881.
134. **Yang MH**, Chiou TJ, Chao TC, Hsiao LT, Chen PM. Delayed rejection after initial engraftment in non-myeloablative bone marrow transplantation. *J Chin Med Assoc* 2003;66: 682-688 .
135. **Yang MH**, Yen CC, Chen PM, Wang WS, Chang YH, Huang WJS, Fan FS, Chiou TJ, Liu JH, Chen KK. A prognostic-factors-based risk-stratification model for invasive urothelial carcinoma of the urinary bladder in Taiwan. *Urology* 2002; 59:232-238.
136. **Yang MH**, Chen KK, Yen CC, Wang, WS, Chang YH, Huang WJS, Fan FS, Chiou TJ, Liu JH, Chen PM. Unusual high incidence of upper-urinary-tract urothelial carcinoma in Taiwan. *Urology* 2002; 59:681-687.
137. Chen PM, **Yang MH**, Yu IT, Lin JT, Lin YC, Fan FS, Wang WS, Yen CC, Chiou TJ, Liu JH. Low incidence of BCL-6 gene alterations for diffuse large B cell lymphomas in Taiwan Chinese. *Cancer* 2002; 94:2635-2644.
138. Chen PM, Yao NS, Wu CM, **Yang MH**, Lin YC, Hsiao LT, Yen CC, Wang WS, Fan FS, Chiou TJ, Liu JH, Lo SJ. Detection of reactivation and genetic mutations of the hepatitis B virus in patients with chronic hepatitis B infections receiving hematopoietic stem cell transplantation. *Transplantation* 2002; 74:282-288.
139. Lin JT, Wang WS, Yen CC, Chiou TJ, Liu JH, Hsiao LT, **Yang MH**, Chao TC, Tai CJ, Chen PM. Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil. *Ann Hematol* 2002 ; 81:723-726.
140. Lin JT, Wang WS, Yen CC, Chiou TJ, Liu JH, Hsiao LT, **Yang MH**, Chao TC, Tai CJ, Chen PM. Myelodysplastic syndrome complicated by autoimmune hemolytic anemia: remission of refractory anemia following mycophenolate mofetil. *Ann Hematol* 2002; 81:723-726.
141. Chen YC, Chiou TJ, **Yang MH**, Yu IT. Two easy-to-perform diagnostic tests for Gilbert's syndrome. *J Chin Med Assoc* 2002;65:231-234.
142. **Yang MH**, Hsu HC. Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review. *Ann Hematol* 2001; 80:299-301.
143. Liu JH, **Yang MH**, Fan FS, Yen CC, Wang WS, Chang YH, Chen KK, Chen PM. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in

- advanced renal cell carcinoma : a phase II study. *Urology* 2001; 57: 650-654.
144. Chen PM, Chiou TJ, Yu IT, Fan FS, Chu CJ, Kao SC, Wang WS, Liu JH, Hsu WM, **Yang MH**, Chao TC, Tai CJ, Hsiao LT, Lin JT, Yen CC. Molecular analysis of mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexa. *Leukemia Lymphoma* 2001; 42:207-214.
145. Hung GY, Chiou TJ, Hsieh YL, **Yang MH**, Chen WYK. Intestinal metastasis causing intussusception in a patient treated for osteosarcoma with history of multiple metastases: a case report. *Jpn J Clin Oncol* 2001; 31: 165-167.
146. **Yang MH**, Ho CH. 2-Chlorodeoxyadenosine (Cladribine) in the treatment of hairy cell leukemia. *J Chin Med Assoc* 2001;64: 54-58.
147. **Yang MH**, Yen CC, Chang YH, Hsieh RK, Liu JH, Chiou TJ, Fan FS, Lin ATL, Huang WJS, Wang WS, Chen KK, Chen PM. Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma : its efficacy and safety in patients even with pretreatment renal insufficiency. *Jpn J Clin Oncol* 2000; 30: 547-552.
148. **Yang MH**, Fan FS, Chen PM, Liu JH, Chiou TJ, Wang WS, Yen CC. Venous gangrene in a patient with adenocarcinoma of lung. *Jpn J Clin Oncol* 2000; 30: 276-278.
149. Yen CC, Liu JH, Wang WS, Fan FS, Chiou TJ, Tai CJ, **Yang MH**, Chao TC, Hsiao LT, Chen PM. Immunophenotypic and genotypic characteristics of chronic myelogenous leukemia in blast crisis. *J Chin Med Assoc* 2000; 63: 785-791.